(Q41159551)

English

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction

scientific article published on 14 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction (English)

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

Josep Tabernero Caturla

5

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

9

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

Gabriel Capella

object named as

Gabriel Capella

10

0 references

8

object named as

Ramon Salazar

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

4

object named as

Paul Roepman

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

Mireille H Snel

6

object named as

Mireille Snel

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

author name string

Sun Tian

1

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

Iris Simon

2

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

Laura van't Veer

7

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

language of work or name

0 references

publication date

14 July 2012

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

62

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

4

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

540-549

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Biological convergence of cancer signatures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Enabling personalized cancer medicine through analysis of gene-expression patterns

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

EGFR associated expression profiles vary with breast tumor subtype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Converting a breast cancer microarray signature into a high-throughput diagnostic test.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Epidermal growth factor receptor targeting in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

A comprehensive pathway map of epidermal growth factor receptor signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Signal transduction and oncogenesis by ErbB/HER receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

27 September 2017

Functional analysis of PIK3CA gene mutations in human colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

17 June 2018

Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

19 August 2018

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

19 August 2018

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

19 August 2018

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

19 August 2018

A module of negative feedback regulators defines growth factor signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

19 August 2018

An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

19 August 2018

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3596735

30 September 2018

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/22798500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/GUTJNL-2012-302423

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

release_u2wtdnjukbfedkfckoeuitikxu

1 reference

https://api.fatcat.wiki/v0/release/u2wtdnjukbfedkfckoeuitikxu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

27 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41159551&oldid=2033466275"